World Bleeding Disorders Treatment Market 2017-2027
Forecast and Analysis by Indication (Haemophilia A, Haemophilia B, Von Willebrand Disease), Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants) and Geography
Bleeding Disorder Treatment – our new study reveals trends, R&D progress, and predicted revenues Where is the Bleeding Disorder Treatment market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead Our 172-page report provides 153 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Bleeding Disorder Treatment market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are forecasts for 7 Bleeding Disorder Treatment Types, each forecasted at a global and regional level.
Bleeding Disorder Treatments, by Indication • Haemophilia A • Haemophilia B • Von Willebrand Disease (VWD) • Other Bleeding Disorders
Bleeding Disorder Treatments, by Drug Class • Plasma-derived Coagulation Factor Concentrates • Factor VIII • Factor IX • Von Willebrand Disease Factor • Prothrombin Complex Concentrate Factor • Recombinant Coagulation Factor Concentrates: – Factor VIII – Factor IX – Von Willebrand Disease Factor • Desmopressin • Antifibrinolytics • Fibrin Sealants • Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 19 leading national markets:
• North America: • The U.S. • Canada • Mexico
• South America: • Brazil • Argentina • Paraguay • Bolivia • Rest of South America
• Europe: • Germany • France • The UK • Italy • Spain • Rest of Europe
• Asia-Pacific: • Japan • China • India • Australia • Thailand • Rest of Asia
• Rest of World (RoW): • Middle East • Africa • Other Countries
The report also includes profiles and for some of the leading companies in the Bleeding Disorder Treatment market, with a focus on this segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, China, India and Australia in particular, will continue to achieve high revenue growth to 2027.
Leading companies and the potential for market growth Overall world revenue for Bleeding Disorder Treatment will surpass $6bn in 2017, our work calculates. We predict strong revenue growth through to 2027.
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Bleeding Disorder Treatment Market report helps you In summary, our 172-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the Bleeding Disorder Treatment market with forecasts for 4 Indications and 5 Drug Classes – discover the industry’s prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 5 regional and 19 key national markets – see forecasts for the Bleeding Disorder treatment market in North America, South America, Europe, Asia-Pacific and the rest of the world. Also analysed are the national markets in the US, Canada, Mexico, Brazil, Argentina, Paraguay, Bolivia, Germany, France, the UK, Italy, Spain, Japan, China, India, Australia, Thailand, the Middle East and Africa. • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the Bleeding Disorder Treatment market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our newly updated report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the Bleeding Disorder Treatment market and leading companies. You will find data, trends and predictions.
Get our report today World Bleeding Disorders Treatment Market 2017-2027: Forecast and Analysis by Indication (Haemophilia A, Haemophilia B, Von Willebrand Disease), Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants) and Geography.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Bleeding Disorders Treatment Market Overview 1.2 Market Definition 1.3 Research Methodology 1.3.1 Primary Research 1.3.2 Secondary Research 1.3.3 Market Evaluation & Forecasting Methodology 1.4 Global Bleeding Disorders Treatment Market Segmentation 1.5 Structure of the Report 1.6 Why You Should Read This Report 1.7 How this Report Delivers 1.8 Key Questions Answered by This Analytical Report 1.9 Frequently Asked Questions (FAQ) 1.10 Who is This Report For? 1.11 Associated Visiongain Reports 1.12 About Visiongain
2. Introduction to Bleeding Disorders Treatment Market
3. Global Bleeding Disorders Treatment Market Forecast to 2027
4. Global Bleeding Disorders Treatment Market by Indication Forecast to 2027 4.1 Overview 4.2 Haemophilia A 4.3 Haemophilia B 4.4 Von Willebrand Disease (VWD) 4.5 Others
5. Global Bleeding Disorders Treatment Market by Drug Class: Market Forecast to 2027 5.1 Overview 5.2 Plasma-derived Coagulation Factor Concentrates 5.2.1 Factor VIII 5.2.2 Factor IX 5.2.3 Von Willebrand Disease Factor 5.2.4 Factor Prothrombin Complex Concentrate 5.3 Recombinant Coagulation Factor Concentrates 5.3.1 Factor VIII 5.3.2 Factor IX 5.3.3 Von Willebrand Disease Factor 5.4 Desmopressin 5.5 Antifibrinolytics 5.6 Fibrin Sealants 5.7 Others
6. Regional Bleeding Disorders Treatment Market Forecasts to 2027 6.1 Regional Bleeding Disorders Treatment Market Forecast Overview 6.2 North American Bleeding Disorders Treatment Market Forecast 2016-2027 6.2.1 USA Bleeding Disorders Treatment Market Forecast 2016-2027 6.2.2 Canada Bleeding Disorders Treatment Market Forecast 2016-2027 6.2.3 Mexico Bleeding Disorders Treatment Market Forecast 2016-2027 6.3 South American Bleeding Disorders Treatment Market Forecast 2016-2027 6.3.1 Brazil Bleeding Disorders Treatment Market Forecast 2016-2027 6.3.2 Argentina Bleeding Disorders Treatment Market Forecast 2016-2027 6.3.3 Paraguay Bleeding Disorders Treatment Market Forecast 2016-2027 6.3.4 Bolivia Bleeding Disorders Treatment Market Forecast 2016-2027 6.3.5 Rest of South America Bleeding Disorders Treatment Market Forecast 2016-2027 6.4 European Bleeding Disorders Treatment Market Forecast 2016-2027 6.4.1 France Bleeding Disorders Treatment Market Forecast 2016-2027 6.4.2 Germany Bleeding Disorders Treatment Market Forecast 2016-2027 6.4.3 UK Bleeding Disorders Treatment Market Forecast 2016-2027 6.4.4 Spain Bleeding Disorders Treatment Market Forecast 2016-2027 6.4.5 Italy Bleeding Disorders Treatment Market Forecast 2016-2027 6.4.6 Rest of Europe Bleeding Disorders Treatment Market Forecast 2016-2027 6.5 Asia-Pacific Bleeding Disorders Treatment Market Forecast 2016-2027 6.5.1 China Bleeding Disorders Treatment Market Forecast 2016-2027 6.5.2 Japan Bleeding Disorders Treatment Market Forecast 2016-2027 6.5.3 India Bleeding Disorders Treatment Market Forecast 2016-2027 6.5.4 Australia Bleeding Disorders Treatment Market Forecast 2016-2027 6.5.5 Thailand Bleeding Disorders Treatment Market Forecast 2016-2027 6.5.6 Rest of Asia-Pacific Bleeding Disorders Treatment Market Forecast 2016-2027 6.6 Rest of World Bleeding Disorders Treatment Market Forecast 2016-2027 6.6.1 Middle East Bleeding Disorders Treatment Market Forecast 2016-2027 6.6.2 Africa Cancer Bleeding Disorders Treatment Forecast 2016-2027 6.6.3 Other Countries Bleeding Disorders Treatment Market Forecast 2016-2027
7. Bleeding Disorders Treatment Market, Qualitative Analysis, 2016-2027 7.1 Porter’s Five Forces Analysis of the Bleeding Disorders Treatment Market 2016-2027 7.1.1 Bargaining Power of Buyers (Low) 7.1.2 Bargaining Power of Suppliers (Medium) 7.1.3 Threat of New Entrants (Low) 7.1.4 Threat of Substitute Products (Low) 7.1.5 Intensity of Competitive Rivalry (High) 7.2 Drivers, Restrains & Opportunities 7.2.1 Drivers 7.2.2 Restraints 7.2.3 Opportunities
9. Conclusions 9.1 Current Leading Segments 9.2 Leading Regional Markets 9.3 Emerging Markets 9.4 The Future of the Market?
10. Glossary Associated Visiongain Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Figures Figure 1.1. Bleeding Disorders Treatment Market Segmentation Figure 2.1 Top winning Strategies of Market Players in Bleeding Disorders Market, 2014-2016 Figure 3.1 Bleeding Disorders Treatment, by Type, ($m), 2016-2027 Figure 3.2 Global Bleeding Disorders Treatment Market, by Drug Class, ($m), 2016-2027 Figure 4.1. Global Bleeding Disorders Treatment Market Forecast, by Type ($m) 2016-2027 Figure 4.2 Bleeding Disorders Treatment Market, by Type, Market Share (%), 2016 Figure 4.3 Global Haemophilia A for Bleeding Disorders Treatment Market Forecast, by Geography, ($m) 2016-2027 Figure 4.4 Global Haemophilia B for Bleeding Disorders Treatment Market Forecast, by Geography, ($m) 2016-2027 Figure 4.5 Global Von Willebrand Disease for Bleeding Disorders Treatment Market Forecast, by Geography, ($m) 2016-2027 Figure 4.6 Global Other Bleeding Disorders Treatment Market Forecast, by Geography, ($m) 2016-2027 Figure 5.1. Global Bleeding Disorder Treatment Market: Drug Class Segmentation Figure 5.2. Global Bleeding Disorders Treatment Market, by Application, Market Share (%), 2016 Figure 5.3. Global Bleeding Disorders Treatment Market for Plasma-derived Coagulation Factor Concentrates Forecast, by Geography($m) 2016-2027 Figure 5.4. Global Bleeding Disorders Treatment Market for Recombinant Coagulation Factor Concentrates Forecast, by Geography($m) 2016-2027 Figure 5.5. Global Bleeding Disorders Treatment Market for Desmopressin Forecast, by Geography($m) 2016-2027 Figure 5.6. Global Bleeding Disorders Treatment Market for Antifibrinolytics Forecast, by Geography($m) 2016-2027 Figure 5.7. Global Bleeding Disorders Treatment Market for Fibrin Sealants Forecast, by Geography($m) 2016-2027 Figure 5.8. Global Bleeding Disorders Treatment Market for Other Drug Classes Forecast, by Geography($m) 2016-2027 Figure 6.1. Global Bleeding Disorders Treatment Market Forecast, by Geography, by Geography($m) 2016-2027 Figure 6.2. Global Bleeding Disorders Treatment Market Forecast, by Geography, Market Share (%), 2016 Figure 6.3. North America Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027 Figure 6.4. North America Bleeding Disorders Treatment Market, by Country, Market Share (%), 2016 Figure 6.5. USA Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.6 Percentage of people with Haemophilia A (Statistic, 2014) Figure 6.7. Canada Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.8 Mexico Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.9 South America Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027 Figure 6.10. South America Bleeding Disorders Treatment Market, by Country, Market Share (%), 2016 Figure 6.11. Brazil Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.12. Argentina Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.13. Paraguay Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.14. Bolivia Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.15. Rest of South America Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.16. Europe Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027 Figure 6.17. Europe Bleeding Disorders Treatment Market, by Country, Market Share (%), 2016 Figure 6.18. France Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.19. Germany Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.20. UK Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.21. Spain Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.22. Italy Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.23. Rest of Europe Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.24. Asia-Pacific Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027 Figure 6.25. Asia-Pacific Bleeding Disorders Treatment Market, Market Share (%), 2016 Figure 6.26. China Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.27. Japan Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.28. India Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.29. Australia Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.30. Thailand Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.31. Rest of Asia-Pacific Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.32. RoW Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027 Figure 6.33. Rest of World Bleeding Disorders Treatment Market, by Country, Market Share (%), 2016 Figure 6.34. Middle East Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.35. Africa Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 6.36. Other Countries Bleeding Disorders Treatment Market Forecast ($m) 2016-2027 Figure 7.1 Porter’s Five Forces Analysis of the Bleeding Disorders Treatment Market Figure 9.1 World Bleeding Disorders Treatment, by Type, ($m), 2016-2027 Figure 9.2 World Bleeding Disorders Treatment, by Drug Type, ($m), 2016-2027 Figure 9.3. World Bleeding Disorders Treatment, by Geography, ($m), 2016-2027
List of Tables Table 2.1 Global Demographics: People suffering from haemophilia and other bleeding disorders Table 3.1. Global Bleeding Disorders Treatment Market Forecast ($m, AGR%, CAGR%) 2016-2027 Table 4.1 Bleeding Disorders Treatment Market, by Type, Forecast ($m, AGR%, CAGR%) 2016-2027 Table 4.2.Key Haemophilia A Drugs approved by FDA Table 4.3. Global Haemophilia A for Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 4.4. Global Haemophilia A for Bleeding Disorders Treatment Market Forecast, by Geography, ($m, AGR%, CAGR%) 2016-2027 Table 4.5.Key Haemophilia B Drugs approved by FDA Table 4.6. Global Haemophilia B for Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 4.7. Global Haemophilia B for Bleeding Disorders Treatment Market Forecast, by Geography ($m, AGR%, CAGR%) 2016-2027 Table 4.8. Global Von Willebrand Disease for Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 4.9. Global Von Willebrand Disease for Bleeding Disorders Treatment Market, by Geography ($m, AGR%, CAGR%) 2016-2027 Table 4.10. Global Other Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 4.11. Global Other Bleeding Disorders Treatment Market Forecast, by Geography ($m, AGR%, CAGR%) 2016-2027 Table 5.1. Global Blood Disorders Treatment Market, by Drug Class($m, AGR%, CAGR%) 2016-2027 Table 5.2. Types of Monoclonal Antibodies Table 5.3. Global Bleeding Disorders Treatment Market for Plasma-Derived Coagulation Factor Concentrates, ($m, AGR%, CAGR%) 2016-2027 Table 5.4. Global Bleeding Disorders Treatment Market for Plasma-derived Coagulation Factor Concentrates, by Geography ($m, AGR%, CAGR%) 2016-2027 Table 5.5. Global Blood Disorders Treatment Market for Recombinant Coagulation Factor Concentrates ($m, AGR%, CAGR%) 2016-2027 Table 5.6. Global Bleeding Disorders Treatment Market for Recombinant Coagulation Factor Concentrates, by Geography ($m, AGR%, CAGR%) 2016-2027 Table 5.7. Global Blood Disorders Treatment Market for Desmopressin ($m, AGR%, CAGR%) 2016-2027 Table 5.8. Global Bleeding Disorders Treatment Market for Desmopressin, by Geography ($m, AGR%, CAGR%) 2016-2027 Table 5.9 Global Blood Disorders Treatment Market for Antifibrinolytics Concentrates ($m, AGR%, CAGR%) 2016-2027 Table 5.10. Global Bleeding Disorders Treatment Market for Antifibrinolytics by Geography ($m, AGR%, CAGR%) 2016-2027 Table 5.11 Global Blood Disorders Treatment Market for Fibrin Sealants ($m, AGR%, CAGR%) 2016-2027 Table 5.12. Global Bleeding Disorders Treatment Market for Fibrin Sealants, by Geography ($m, AGR%, CAGR%) 2016-2027 Table 5.13. Global Blood Disorders Treatment Market for Others ($m, AGR%, CAGR%) 2016-2027 Table 5.14. Global Bleeding Disorders Treatment Market for Others, by Geography ($m, AGR%, CAGR%) 2016-2027 Table 6.1. Global Bleeding Disorders Treatment Market Forecast, by Geography ($m, AGR%, CAGR%) 2016-2027 Table 6.2. North America Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027 Table 6.3. USA Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.4. Canada Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.5. Mexico Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.6. South America Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027 Table 6.7. Brazil Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.8. Argentina Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.9. Paraguay Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.10. Bolivia Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.11. Rest of South America Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.12. European Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027 Table 6.13. France Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.14. Germany Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.15. UK Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.16. Spain Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.17. Italy Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.18. Rest of European Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.19. Asia-Pacific Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027 Table 6.20. China Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.21. Japan Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.22. India Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.23. Australia Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.24. Thailand Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.25. Rest of Asia-Pacific Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.26. Rest of World Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027 Table 6.27. Middle East Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.28. Africa Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 6.29. Other Countries Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027 Table 8.1. Novo Nordisk: Financial Overview Table 8.2. Novo Nordisk: Financial Overview Table 8.3. Novo Nordisk: Product Portfolio Table 8.4. Novo Nordisk: Recent Developments Table 8.5. Bristol-Myers Squibb: Company Overview Table 8.6. Bristol Myers Squibb: Financial Overview Table 8.7. Bristol-Myers Squibb: Product Portfolio Table 8.8. Pfizer Inc.: Company Overview Table 8.9. Pfizer, Inc.: Financial Overview Table 8.10. Pfizer Inc.: Product Portfolio Table 8.11. Pfizer Inc.: Recent Development Table 8.12. Bayer AG: Company Overview Table 8.13. Bristol Myers Squibb: Financial Overview Table 8.14. Bayer AG: Product Portfolio Table 8.15. Bayer AG: Recent Development Table 8.16. CSL Company Overview Table 8.17. CSL: Financial Overview Table 8.18. CSl: Product Portfolio Table 8.19. CSL: Recent Development Table 8.20. Grifols: Company Overview Table 8.21. Grifols: Financial Overview Table 8.22 Grifols: Product Portfolio Table 8.23. Octapharma: Company Overview Table 8.24. Octapharma: Financial Overview Table 8.25 Octapharma: Product Portfolio Table 8.26. Octapharma: Recent Development Table 8.27. Shire: Company Overview Table 8.28. Shire: Financial Overview Table 8.29. Shire: Product Portfolio Table 8.30. Shire: Recent Development Table 8.31. Sanofi: Company Overview Table 8.32. Sanofi: Financial Overview Table 8.33. Sanofi: Product Portfolio Table 8.34. Kedrion: Company Overview Table 8.35. Kedrion: Financial Overview Table 8.36. Kedrion: Product Portfolio Table 8.37. Kedrion: Recent Development Table 8.38 Other Companies for Bleeding Disorders Treatment Market Table 9.1 Global Demographics: People suffering from haemophilia and other bleeding disorders
Abbott Laboratories AbbVie, Inc. Aetna, Inc. Alkermes Plc Amarin Corp. Plc Amgen, Inc. Array BioPharma, Inc. Associates Of Cape Cod Inc. Astex Pharmaceuticals Inc. AstraZeneca Plc Bayer AG Bayer Corporation Bayer HealthCare AG Bayer Schering Pharma Aktiengesellschaft BioMarin Pharmaceutical, Inc. Biotest AG Bristol-Myers Squibb Co. Cardax, Inc. Cardinal Health, Inc. Ceapro, Inc. Celgene Corp. Centene Corp. Cephalon, Inc. Chugai Pharmaceutical Co., Ltd. CK Life Sciences International (Holdings), Inc. Cornerstone Research & Development Inc. CTI BioPharma Corp. Domain Therapeutics SA Emd Millipore Corporation Emd Serono Inc. Endo International Plc Evotec AG GlaxoSmithKline Plc Janssen Biotech, Inc. JHL Biotech, Inc. Johnson & Johnson Laboratoire Theramex Lonza Group AG McKesson Corp. Merck KGaA MorphoSys AG Motif Bio Plc Myrexis, Inc. NBTY, Inc. Neptune Technologies & Bioresources, Inc. Nexvet Biopharma PLC Nordion Inc Novartis AG Opexa Therapeutics, Inc. Otsuka Pharmaceutical Co. Ltd. Owens & Minor, Inc. Panacos Pharmaceuticals, Inc. Pfizer Inc. Pharma Mar SA Premier Healthcare Alliance L.P. Quanterix Corp. Samsung BioLogics Co., Ltd. Sangers (Northern Ireland) Limited Sanofi Spectrum Pharmaceuticals, Inc. Taiho Pharmaceutical Co. Ltd. Takeda Pharmaceutical Co., Ltd. UnitedHealth Group, Inc. Verastem, Inc. Vertex Pharmaceuticals, Inc. Windtree Therapeutics, Inc. Zogenix, Inc.
Organizations Mentioned in the Report American College of Nutrition Australian Institute of Health and Welfare European Medicines Agency Health Canada International Medical Corps National Cancer Institute National Health Service The American Society of Clinical Oncology Inc The Feinstein Institute for Medical Research The National Institute for Health and Clinical Excellence United States Department of Health & Human Services World Health Organization
Download sample pages
Complete the form below to download your free sample pages for World Bleeding Disorders Treatment Market 2017-2027
Download sample pages
Complete the form below to download your free sample pages for World Bleeding Disorders Treatment Market 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
